What we're reading, September 28, 2016: a new company will help people fight their medical bills; prescription drug monitoring programs may not be helping the opioid crisis; and why banning pay-for-delay deals may not help to lower costs.
A new start-up company is helping people fight their medical bills by connecting their insurance to a platform for constant scrutiny of every claim. According to The Atlantic, the service doesn’t come cheap, with Remedy taking 20% of the savings. There is currently a $99 cap in place for a single bill, but that could change. Remedy’s business is built around the fact that statistics show medical errors are responsible for $120 to $150 billion in overcharges each year.
Prescription drug monitoring programs may not be helping the opioid crisis, after all. These state-run databases are supposed to turn up evidence of abuse, but may make things worse as addicts start looking to street drugs for their fix, reported Politico. The programs have helped identify patients who doctor shop or doctors who overprescribe painkillers, but new data show that in many of the states using a drug monitoring database, heroin overdoses are skyrocketing.
One of Hillary Clinton’s proposals to lower drug costs is to ban “pay-for-delay” deals. However, this strategy may not be very effective, according to an opinion piece in STAT. Through pay-for-delay deals, drug companies with a branded drug offer to pay a generic company to stay out of the market for a set number of years. Unfortunately, these settlements are difficult to uncover, which means a more nuanced approach to reining in drug prices is necessary.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More